18.12.2012 Views

joint strategic needs assessment foundation profile - JSNA

joint strategic needs assessment foundation profile - JSNA

joint strategic needs assessment foundation profile - JSNA

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Interative Hull Atlas: www.hullpublichealth.org/Pages/hull_atlas.htm More information: www.jsnaonline.org and www.hullpublichealth.org<br />

Overall, 13.8% of all clinician episodes for cancer were for malignant neoplasm related<br />

to the lymphoid, haematopoietic and related tissue which includes leukaemia, a further<br />

13.4% for lung cancer, 11.9% for breast cancer, 11.2% for bladder cancer, and 10.3%<br />

for colorectal cancer (Table 233).<br />

In-patient admission rates provide useful information about the general level of illness<br />

and the use of hospital services within geographical areas. It is very important to note<br />

that admission rates depend on how willing people are to make use of medical services,<br />

the location and accessibility of services, as well as differences in referral patterns and<br />

practices within primary and secondary care (see page 179 for more discussion).<br />

Table 233: Total number of daycase and inpatient clinician episodes with primary<br />

diagnosis of cancer over three year period 2007/08 to 2009/10<br />

ICD 10 code Cancer type Total cancer clinician<br />

episodes 2007/08 to<br />

2009/10<br />

Number Percentage<br />

C00-C14 Lip, oral cavity & pharynx cancer 407 1.8<br />

C15 Oesophagus cancer 609 2.7<br />

C16 Stomach cancer 509 2.3<br />

C17-C21 Colorectal cancer 2,293 10.3<br />

C25 Pancreas cancer 573 2.6<br />

C22-C24, C26 Other digestive system cancers 266 1.2<br />

C32 Larynx cancer 204 0.9<br />

C33-C34 Lung cancer 2,989 13.4<br />

C40-C41 Bone and articular cartilage 41 0.2<br />

C43 Malignant melanoma 139 0.6<br />

C44 Other malignant neoplasms of the skin 809 3.6<br />

C45 Mesothelioma cancer 84 0.4<br />

C46-C49 Soft tissue 193 0.9<br />

C50 Breast cancer 2,640 11.9<br />

C53 Cervical cancer 244 1.1<br />

C56 Ovary cancer 494 2.2<br />

C61 Prostate cancer 435 2.0<br />

C51-63 excl C53,C56&C61 Other reproductive system cancers 448 2.0<br />

C64 Kidney cancer 255 1.1<br />

C67 Bladder cancer 2,465 11.1<br />

C65-C66, C68 Other urinary tract organs 65 0.3<br />

C71 Brain cancer 282 1.3<br />

C76-C80 Ill-defined, secondary or unspecified sites 2480 11.2<br />

C91-C95 Leukaemia 1,108 5.0<br />

C81-C90, C96 Other lymphoid/haematopoietic/related 1,954 8.8<br />

C00-C97 excl above Other cancers 239 1.1<br />

Total cancer clinician episodes 22,225 100.0<br />

Joint Strategic Needs Assessment Foundation Profile – Hull Health Profile: Release 3. March 2011. 511

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!